LBA18 Pembrolizumab or placebo plus chemotherapy followed by pembrolizumab or placebo for early-stage TNBC: Updated EFS results from the phase III KEYNOTE-522 study
Schmid P, Cortés J, Dent R, Pusztai L, McArthur H, Kummel S, Denkert C, Park Y, Hui R, Harbeck N, Takahashi M, Foukakis T, Reynier M, Ferreira M, Im S, Cardoso F, Ding Y, Pan W, Tryfonidis K, O'Shaughnessy J. LBA18 Pembrolizumab or placebo plus chemotherapy followed by pembrolizumab or placebo for early-stage TNBC: Updated EFS results from the phase III KEYNOTE-522 study. Annals Of Oncology 2023, 34: s1257. DOI: 10.1016/j.annonc.2023.10.008.Peer-Reviewed Original Research